NASDAQ:CMTA - Clementia Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$18.74 +0.41 (+2.24 %)
(As of 05/22/2018 06:00 AM ET)
Previous Close$18.74
Today's Range$17.46 - $18.74
52-Week Range$11.72 - $20.15
Volume34,887 shs
Average Volume29,836 shs
Market Capitalization$581.39 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Clementia Pharmaceuticals (NASDAQ:CMTA)

Clementia Pharmaceuticals logoClementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.

Receive CMTA News and Ratings via Email

Sign-up to receive the latest news and ratings for CMTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CMTA
CUSIPN/A
Phone514-940-3600

Debt

Debt-to-Equity RatioN/A
Current Ratio7.06
Quick Ratio7.06

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.47 per share
Price / Book4.19

Profitability

EPS (Most Recent Fiscal Year)($7.93)
Net Income$-115,450,000.00
Net MarginsN/A
Return on Equity-165.55%
Return on Assets-71.97%

Miscellaneous

Employees30
Outstanding Shares31,720,000

Clementia Pharmaceuticals (NASDAQ:CMTA) Frequently Asked Questions

What is Clementia Pharmaceuticals' stock symbol?

Clementia Pharmaceuticals trades on the NASDAQ under the ticker symbol "CMTA."

How were Clementia Pharmaceuticals' earnings last quarter?

Clementia Pharmaceuticals Inc (NASDAQ:CMTA) posted its quarterly earnings results on Wednesday, May, 9th. The company reported ($0.42) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.33) by $0.09. View Clementia Pharmaceuticals' Earnings History.

When is Clementia Pharmaceuticals' next earnings date?

Clementia Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Clementia Pharmaceuticals.

What price target have analysts set for CMTA?

5 brokerages have issued twelve-month target prices for Clementia Pharmaceuticals' stock. Their forecasts range from $23.00 to $32.00. On average, they anticipate Clementia Pharmaceuticals' stock price to reach $26.60 in the next year. View Analyst Ratings for Clementia Pharmaceuticals.

Who are some of Clementia Pharmaceuticals' key competitors?

Who are Clementia Pharmaceuticals' key executives?

Clementia Pharmaceuticals' management team includes the folowing people:
  • Dr. Clarissa Desjardins, Founder, Pres, CEO & Director (Age 51)
  • Mr. Michael Singer, CFO & Corp. Sec. (Age 53)
  • Dr. Donna Roy Grogan M.D., Chief Medical Officer (Age 61)
  • Mr. Jeffery Packman, Chief Devel. Officer (Age 51)
  • Mr. Eric Grinstead, Chief Commercial Officer (Age 61)

When did Clementia Pharmaceuticals IPO?

(CMTA) raised $101 million in an initial public offering (IPO) on Wednesday, August 2nd 2017. The company issued 7,200,000 shares at $13.00-$15.00 per share. Morgan Stanley and Leerink Partners served as the underwriters for the IPO and Wedbush Securities and BTIG were co-managers.

Has Clementia Pharmaceuticals been receiving favorable news coverage?

Headlines about CMTA stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Clementia Pharmaceuticals earned a coverage optimism score of 0.14 on Accern's scale. They also assigned headlines about the company an impact score of 47.13 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Clementia Pharmaceuticals' major shareholders?

Clementia Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include JPMorgan Chase & Co. (2.35%), Sphera Funds Management LTD. (0.63%), Artal Group S.A. (0.63%), DAFNA Capital Management LLC (0.33%), Alps Advisors Inc. (0.13%) and Birchview Capital LP (0.12%). View Institutional Ownership Trends for Clementia Pharmaceuticals.

Which institutional investors are buying Clementia Pharmaceuticals stock?

CMTA stock was bought by a variety of institutional investors in the last quarter, including Artal Group S.A., DAFNA Capital Management LLC, JPMorgan Chase & Co., Sphera Funds Management LTD., Birchview Capital LP, A.R.T. Advisors LLC and Alps Advisors Inc.. View Insider Buying and Selling for Clementia Pharmaceuticals.

How do I buy shares of Clementia Pharmaceuticals?

Shares of CMTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Clementia Pharmaceuticals' stock price today?

One share of CMTA stock can currently be purchased for approximately $18.74.

How big of a company is Clementia Pharmaceuticals?

Clementia Pharmaceuticals has a market capitalization of $581.39 million. The company earns $-115,450,000.00 in net income (profit) each year or ($7.93) on an earnings per share basis. Clementia Pharmaceuticals employs 30 workers across the globe.

How can I contact Clementia Pharmaceuticals?

Clementia Pharmaceuticals' mailing address is 4150 ST CATHERINE STREET WEST SUITE 550, MONTREAL A8, H3Z 2Y5. The company can be reached via phone at 514-940-3600 or via email at [email protected]


MarketBeat Community Rating for Clementia Pharmaceuticals (CMTA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  88 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  180
MarketBeat's community ratings are surveys of what our community members think about Clementia Pharmaceuticals and other stocks. Vote "Outperform" if you believe CMTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CMTA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Clementia Pharmaceuticals (NASDAQ:CMTA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Clementia Pharmaceuticals in the last 12 months. Their average twelve-month price target is $26.60, suggesting that the stock has a possible upside of 41.94%. The high price target for CMTA is $32.00 and the low price target for CMTA is $23.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $26.60$26.60$27.00$27.00
Price Target Upside: 41.94% upside61.31% upside64.43% upside64.43% upside

Clementia Pharmaceuticals (NASDAQ:CMTA) Consensus Price Target History

Price Target History for Clementia Pharmaceuticals (NASDAQ:CMTA)

Clementia Pharmaceuticals (NASDAQ:CMTA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2018B. RileyInitiated CoverageBuy$25.00MediumView Rating Details
11/14/2017WedbushReiterated RatingOutperform$26.00N/AView Rating Details
8/31/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$32.00LowView Rating Details
8/28/2017Leerink SwannInitiated CoverageOutperform ➝ Outperform$23.00HighView Rating Details
8/28/2017Morgan StanleyInitiated CoverageOverweight ➝ Overweight$27.00HighView Rating Details
(Data available from 5/22/2016 forward)

Earnings

Clementia Pharmaceuticals (NASDAQ:CMTA) Earnings History and Estimates Chart

Earnings by Quarter for Clementia Pharmaceuticals (NASDAQ:CMTA)

Clementia Pharmaceuticals (NASDAQ:CMTA) Earnings Estimates

2018 EPS Consensus Estimate: ($1.52)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.36)($0.28)($0.32)
Q2 20182($0.46)($0.29)($0.38)
Q3 20182($0.49)($0.31)($0.40)
Q4 20182($0.52)($0.33)($0.43)

Clementia Pharmaceuticals (NASDAQ CMTA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/23/2018($0.33)N/AView Earnings Details
5/9/20183/31/2018($0.33)($0.42)ViewN/AView Earnings Details
2/28/2018Q4 2017($0.34)($0.37)ViewN/AView Earnings Details
11/13/2017Q3 2017($0.31)($1.83)ViewN/AView Earnings Details
8/10/2017Q2 2017($9.54)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Clementia Pharmaceuticals (NASDAQ:CMTA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Clementia Pharmaceuticals (NASDAQ CMTA) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 71.24%
Insider Trading History for Clementia Pharmaceuticals (NASDAQ:CMTA)
Institutional Ownership by Quarter for Clementia Pharmaceuticals (NASDAQ:CMTA)

Clementia Pharmaceuticals (NASDAQ CMTA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Clementia Pharmaceuticals (NASDAQ CMTA) News Headlines

Source:
DateHeadline
Clementia Pharmaceuticals (CMTA) Receives Average Recommendation of "Buy" from AnalystsClementia Pharmaceuticals (CMTA) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 17 at 2:08 PM
Clementia Pharmaceuticals (CMTA) Scheduled to Post Earnings on WednesdayClementia Pharmaceuticals (CMTA) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - May 16 at 1:52 AM
Clementia Pharmaceuticals (CMTA) Cut to "Sell" at Zacks Investment ResearchClementia Pharmaceuticals (CMTA) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 14 at 8:10 PM
Brokers Offer Predictions for Clementia Pharmaceuticals FY2018 Earnings (CMTA)Brokers Offer Predictions for Clementia Pharmaceuticals' FY2018 Earnings (CMTA)
www.americanbankingnews.com - May 14 at 3:46 AM
Wedbush Research Analysts Lower Earnings Estimates for Clementia Pharmaceuticals (CMTA)Wedbush Research Analysts Lower Earnings Estimates for Clementia Pharmaceuticals (CMTA)
www.americanbankingnews.com - May 14 at 2:36 AM
Clementia Pharmaceuticals (CMTA) Issues Quarterly  Earnings ResultsClementia Pharmaceuticals (CMTA) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 5:41 PM
Clementia Reports First Quarter 2018 Operating Results and Pipeline UpdatesClementia Reports First Quarter 2018 Operating Results and Pipeline Updates
finance.yahoo.com - May 9 at 9:34 AM
 Analysts Anticipate Clementia Pharmaceuticals (CMTA) Will Post Earnings of -$0.33 Per Share Analysts Anticipate Clementia Pharmaceuticals (CMTA) Will Post Earnings of -$0.33 Per Share
www.americanbankingnews.com - May 6 at 5:25 PM
Clementia Pharmaceuticals (CMTA) Stock Rating Upgraded by ValuEngineClementia Pharmaceuticals (CMTA) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 3 at 10:35 PM
Wired News - Clementia Commenced Phase-2 MO-Ped Trial for Palovarotene in Pediatric Patients with Multiple OsteochondromasWired News - Clementia Commenced Phase-2 MO-Ped Trial for Palovarotene in Pediatric Patients with Multiple Osteochondromas
finance.yahoo.com - April 24 at 9:30 AM
Clementia Pharmaceuticals (CMTA) Given Average Rating of "Buy" by BrokeragesClementia Pharmaceuticals (CMTA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 22 at 9:32 AM
Clementia launches mid-stage study of palovarotene in pediatric bone tumorsClementia launches mid-stage study of palovarotene in pediatric bone tumors
seekingalpha.com - April 20 at 9:44 AM
Clementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple OsteochondromasClementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple Osteochondromas
finance.yahoo.com - April 20 at 9:44 AM
Zacks: Analysts Anticipate Clementia Pharmaceuticals (CMTA) Will Post Earnings of -$0.33 Per ShareZacks: Analysts Anticipate Clementia Pharmaceuticals (CMTA) Will Post Earnings of -$0.33 Per Share
www.americanbankingnews.com - April 19 at 5:20 PM
 Brokerages Anticipate Clementia Pharmaceuticals (CMTA) Will Announce Earnings of -$0.33 Per Share Brokerages Anticipate Clementia Pharmaceuticals (CMTA) Will Announce Earnings of -$0.33 Per Share
www.americanbankingnews.com - April 2 at 7:10 PM
FY2018 Earnings Estimate for Clementia Pharmaceuticals (CMTA) Issued By B. RileyFY2018 Earnings Estimate for Clementia Pharmaceuticals (CMTA) Issued By B. Riley
www.americanbankingnews.com - March 30 at 7:05 AM
Analyst: Clementia Has Potential To Reach Unmet Market For Rare Bone DiseaseAnalyst: Clementia Has Potential To Reach Unmet Market For Rare Bone Disease
finance.yahoo.com - March 29 at 9:55 AM
Clementia Pharmaceuticals (CMTA) Given Consensus Recommendation of "Buy" by BrokeragesClementia Pharmaceuticals (CMTA) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 28 at 10:17 AM
B. Riley Begins Coverage on Clementia Pharmaceuticals (CMTA)B. Riley Begins Coverage on Clementia Pharmaceuticals (CMTA)
www.americanbankingnews.com - March 28 at 8:06 AM
Zacks: Clementia Pharmaceuticals Inc (CMTA) Given Consensus Rating of "Strong Buy" by AnalystsZacks: Clementia Pharmaceuticals Inc (CMTA) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - March 23 at 1:32 AM
Clementia Pharmaceuticals (CMTA) Rating Increased to Hold at Zacks Investment ResearchClementia Pharmaceuticals (CMTA) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 20 at 8:16 PM
-$0.33 Earnings Per Share Expected for Clementia Pharmaceuticals Inc (CMTA) This Quarter-$0.33 Earnings Per Share Expected for Clementia Pharmaceuticals Inc (CMTA) This Quarter
www.americanbankingnews.com - March 16 at 3:06 PM
 Clementia Pharmaceuticals Inc (CMTA) Receives Average Rating of "Strong Buy" from Analysts Clementia Pharmaceuticals Inc (CMTA) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - March 8 at 3:28 AM
Zacks Investment Research Lowers Clementia Pharmaceuticals (CMTA) to SellZacks Investment Research Lowers Clementia Pharmaceuticals (CMTA) to Sell
www.americanbankingnews.com - March 7 at 8:34 PM
Sectoral Asset Management Inc Raises Stake in Clementia Pharmaceuticals Inc (CMTA)Sectoral Asset Management Inc Raises Stake in Clementia Pharmaceuticals Inc (CMTA)
www.americanbankingnews.com - March 6 at 2:11 PM
Clementia to Present at the Cowen and Company 38th Annual Health Care ConferenceClementia to Present at the Cowen and Company 38th Annual Health Care Conference
finance.yahoo.com - March 6 at 9:24 AM
Clementia Pharmaceuticals Inc (CMTA) to Post FY2019 Earnings of ($1.67) Per Share, Wedbush ForecastsClementia Pharmaceuticals Inc (CMTA) to Post FY2019 Earnings of ($1.67) Per Share, Wedbush Forecasts
www.americanbankingnews.com - March 5 at 8:50 AM
Clementia Pharmaceuticals Inc (CMTA) Short Interest Down 60.0% in FebruaryClementia Pharmaceuticals Inc (CMTA) Short Interest Down 60.0% in February
www.americanbankingnews.com - March 4 at 1:40 AM
Brokerages Expect Clementia Pharmaceuticals Inc (CMTA) to Post ($0.31) EPSBrokerages Expect Clementia Pharmaceuticals Inc (CMTA) to Post ($0.31) EPS
www.americanbankingnews.com - March 2 at 7:12 PM
Clementia Reports 2017 Operating Results and Business HighlightsClementia Reports 2017 Operating Results and Business Highlights
finance.yahoo.com - February 28 at 4:56 PM
Zacks: Analysts Expect Clementia Pharmaceuticals Inc (CMTA) to Announce -$0.34 Earnings Per ShareZacks: Analysts Expect Clementia Pharmaceuticals Inc (CMTA) to Announce -$0.34 Earnings Per Share
www.americanbankingnews.com - February 27 at 3:16 PM
Clementia Pharmaceuticals Inc Forecasted to Post Q1 2018 Earnings of ($0.28) Per Share (CMTA)Clementia Pharmaceuticals Inc Forecasted to Post Q1 2018 Earnings of ($0.28) Per Share (CMTA)
www.americanbankingnews.com - February 23 at 10:02 AM
Clementia Pharmaceuticals Inc to Post FY2022 Earnings of $1.35 Per Share, Leerink Swann Forecasts (CMTA)Clementia Pharmaceuticals Inc to Post FY2022 Earnings of $1.35 Per Share, Leerink Swann Forecasts (CMTA)
www.americanbankingnews.com - February 22 at 4:34 PM
 Clementia Pharmaceuticals Inc (CMTA) Receives Consensus Recommendation of "Strong Buy" from Analysts Clementia Pharmaceuticals Inc (CMTA) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - February 15 at 12:46 PM
Zacks: Brokerages Anticipate Clementia Pharmaceuticals Inc (CMTA) Will Announce Earnings of -$0.34 Per ShareZacks: Brokerages Anticipate Clementia Pharmaceuticals Inc (CMTA) Will Announce Earnings of -$0.34 Per Share
www.americanbankingnews.com - February 10 at 11:08 PM
Clementia to Participate in Leerink Partners 7th Annual Global Healthcare ConferenceClementia to Participate in Leerink Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 7 at 9:11 AM
Clementia Pharmaceuticals (CMTA) vs. Its Competitors Head to Head ContrastClementia Pharmaceuticals (CMTA) vs. Its Competitors Head to Head Contrast
www.americanbankingnews.com - February 4 at 9:08 PM
Clementia Appoints Industry Veteran Pierre Legault to its Board of DirectorsClementia Appoints Industry Veteran Pierre Legault to its Board of Directors
finance.yahoo.com - January 31 at 9:20 AM
Clementia Pharmaceuticals (CMTA) Stock Rating Upgraded by Zacks Investment ResearchClementia Pharmaceuticals (CMTA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - January 30 at 8:38 PM
Zacks: Clementia Pharmaceuticals Inc (CMTA) Given Average Rating of "Strong Buy" by BrokeragesZacks: Clementia Pharmaceuticals Inc (CMTA) Given Average Rating of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 30 at 7:46 AM
 Analysts Anticipate Clementia Pharmaceuticals Inc (CMTA) to Post -$0.34 EPS Analysts Anticipate Clementia Pharmaceuticals Inc (CMTA) to Post -$0.34 EPS
www.americanbankingnews.com - January 25 at 1:24 AM
Clementia Pharmaceuticals Incs Lock-Up Period To Expire  on January 29th (NASDAQ:CMTA)Clementia Pharmaceuticals Inc's Lock-Up Period To Expire on January 29th (NASDAQ:CMTA)
www.americanbankingnews.com - January 22 at 1:28 AM
Clementia Pharmaceuticals (CMTA) Downgraded to "Sell" at Zacks Investment ResearchClementia Pharmaceuticals (CMTA) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 15 at 10:28 PM
 Brokerages Set $27.00 Target Price for Clementia Pharmaceuticals Inc (CMTA) Brokerages Set $27.00 Target Price for Clementia Pharmaceuticals Inc (CMTA)
www.americanbankingnews.com - January 15 at 5:38 PM
 Analysts Set $27.00 Price Target for Clementia Pharmaceuticals Inc (CMTA) Analysts Set $27.00 Price Target for Clementia Pharmaceuticals Inc (CMTA)
www.americanbankingnews.com - January 10 at 1:44 AM
Zacks: Clementia Pharmaceuticals Inc (CMTA) Receives Consensus Recommendation of "Strong Buy" from BrokeragesZacks: Clementia Pharmaceuticals Inc (CMTA) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - December 26 at 9:52 AM
Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans ProgressivaClementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva
finance.yahoo.com - December 12 at 9:14 AM
Zacks: Clementia Pharmaceuticals Inc. (CMTA) Given $27.00 Average Target Price by AnalystsZacks: Clementia Pharmaceuticals Inc. (CMTA) Given $27.00 Average Target Price by Analysts
www.americanbankingnews.com - December 11 at 7:14 PM
Form 6-K Clementia Pharmaceutical For: Dec 05Form 6-K Clementia Pharmaceutical For: Dec 05
www.streetinsider.com - December 5 at 5:51 PM
 Clementia Pharmaceuticals Inc. (CMTA) Given $27.00 Average Target Price by Brokerages Clementia Pharmaceuticals Inc. (CMTA) Given $27.00 Average Target Price by Brokerages
www.americanbankingnews.com - November 21 at 11:50 PM

SEC Filings

Clementia Pharmaceuticals (NASDAQ:CMTA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Clementia Pharmaceuticals (NASDAQ:CMTA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Clementia Pharmaceuticals (NASDAQ CMTA) Stock Chart for Tuesday, May, 22, 2018

Loading chart…

This page was last updated on 5/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.